Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Mazigh Fares *Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0002-6003-9244
Melanie McFarlane *Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0002-8392-2291
Rhys H Parry *School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia 4072, Australia.ORCID 0000-0001-9238-1952
Rozeena Arif *Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0009-0007-0492-6352
Andrew T ClarkeMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0001-7271-3833
Wael KamelMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0002-7625-2648
Kelsey DaviesMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0009-0009-5624-5983
Riona Datta-SavageBiomedical Sciences Research Complex, University of St Andrews, St Andrews, Scotland KY16 9ST, United Kingdom.ORCID 0009-0001-3718-0733
Ulrich Schwarz-LinekBiomedical Sciences Research Complex, University of St Andrews, St Andrews, Scotland KY16 9ST, United Kingdom.ORCID 0000-0003-0526-223X
Lesley Bell-SakyiDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L3 5RF, United Kingdom.ORCID 0000-0002-7305-0477
Marine J PetitMicrobes, Infection and Immunity, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7YH, United Kingdom.ORCID 0000-0001-7427-7203
Esther SchnettlerBernhard-Nocht-Institute for Tropical Medicine, Hamburg 20359, Germany.ORCID 0000-0001-8141-3728
Alfredo CastelloMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0002-1499-4662
Alain KohlMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0002-1523-9458
Benjamin BrennanMedical Research Council-University of Glasgow Centre for Virus Research, Glasgow, Scotland G61 1QH, United Kingdom.ORCID 0000-0003-4707-726X
Funding
Deutsches Zentrum für Infektionsforschung (DZIF) TTU 01.708EC | European Research Council (ERC) 101001634EC | Horizon 2020 Framework Programme (H2020) 890970Medical Research Future Fund MRF2022950UKRI | Biotechnology and Biological Sciences Research Council (AFRC) BB/P024270/1UKRI | Medical Research Council (MRC) MC_UU_00034/2UKRI | Medical Research Council (MRC) MC_UU_00034/4UKRI | Medical Research Council (MRC) MC_UU_00034/8UKRI | Medical Research Council (MRC) MC_UU_12014/8UKRI | Medical Research Council (MRC) MR/R021562/1UKRI | Medical Research Council (MRC) MR/W018608/1Wellcome TrustWellcome Trust (WT) 210462/Z/18/ZWellcome Trust (WT) 223743/Z/21/Z
6 · The paper itself
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne phenuivirus causing high mortality in humans. While the nonstructural protein NSs is dispensable for replication in interferon-deficient mammalian cells, we demonstrate that NSs is essential for viral replication in tick cells. SFTSV infection triggers canonical Dicer-2-mediated antiviral RNA interference (RNAi) in tick cells, producing virus-derived small interfering RNAs (siRNAs) that target viral transcripts for degradation. We show that NSs functions as a viral suppressor of RNAi by selectively engaging and depleting single-stranded RNAs derived from 22-nucleotide siRNAs, likely limiting their incorporation into RNA-induced silencing complexes (RISC). Complementation with a heterologous RNAi suppressor (p19 protein) partially rescues replication of NSs-deficient virus, validating the RNAi-suppressive function of NSs. These findings reveal that successful tick-borne viral replication requires host-specific immune evasion strategies and establish NSs-mediated RNAi suppression as essential for SFTSV persistence in arthropod vectors.
Indexed as
PhlebovirusRNA InterferenceTicksViral Nonstructural ProteinsAnimalsCell LineHost-Pathogen InteractionsHumansRNA ReplicationRNA, Small InterferingRNA, ViralVirus ReplicationRNA, Small InterferingRNA, ViralViral Nonstructural Proteinsarthropod innate immune evasionbunyavirushost–virus interactionssevere fever with thrombocytopenia syndrome virustick cell line
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SFTSV NSs protein is a tick antiviral RNAi response suppressor. · full record | OpenQuestion